Abstracts tagged "cartilage"

Abstract Number: 1149 • 2015 ACR/ARHP Annual Meeting
The Active Metabolite of Fostamatinib, R406, Only Decreases the Inflammation-Driven Extracellular Matrix Turnover of the Joint at High Concentrations Ex Vivo
Cecilie F. Kjelgaard-Petersen^1,2, Christian S. Thudium¹, Anne Sofie Siebuhr¹, Thorbjørn G. Christiansen³, Morten Asser Karsdal¹, Per Hägglund² and Anne C. Bay-Jensen⁴, ¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark, ³Gentofte University Hospital, Orthopaedicsurgery unit, Gentofte, Denmark, ⁴Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) and rheumatoid arthritis are degenerative diseases of the whole joint. The extracellular matrix (ECM) turnover is highly regulated in response to the…
Abstract Number: 1152 • 2015 ACR/ARHP Annual Meeting
Comprehensive Novel Proteomic Analysis of RA Synovial Fluid Highlights the Distinct Protein Profiles of Bone and Cartilage Metabolism
Yasushi Kondo¹, Katsuya Suzuki¹, Masaru Takeshita², Yoshiaki Kassai³, Keiko Koga³, Yuumi Gotou⁴, Takahiro Miyazaki³, Rimpei Morita⁵, Yasuo Niki⁶, Atsuko Murota¹, Ayumi Nishikawa¹, Hironari Hanaoka¹, Yuko Kaneko⁷, Hidekata Yasuoka⁷, Kunihiro Yamaoka¹, Akihiko Yoshimura⁵ and Tsutomu Takeuchi⁸, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd., Kanagawa, Japan, ⁴Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, ⁵Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan, ⁶Department of Orthopaedic Surgery, Keio University, Tokyo, Japan, ⁷Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁸Dept. of Internal Medicine, School of Medicine Keio University, Tokyo, Japan
Background/Purpose: Growing interest has arisen in the search for specific pathophysiology and biomarker for rheumatoid arthritis (RA) utilizing synovial fluid (SF) proteomic analysis. However the…
Abstract Number: 1162 • 2015 ACR/ARHP Annual Meeting
IL37 Reduces Pro-Inflammatory Cytokine and Catabolic Enzyme Production in Human Chondrocytes: A Protective Role in Osteoarthritis?
Ellen van Geffen¹, Arjan van Caam², Elly Vitters², Henk van Beuningen², Esmeralda Blaney Davidson² and Peter M. van der Kraan², ¹Experimential Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Osteoarthritis (OA) is the most common joint disease, primarily characterized by progressive articular cartilage degradation. Cartilage destruction is assumed to be mediated by pro-inflammatory…
Abstract Number: 1312 • 2015 ACR/ARHP Annual Meeting
Radiocarpal Cartilage Matrix Changes 3-Months after Anti-TNF Treatment for Rheumatoid Arthritis – Feasibility Study Using MR T1ρ� Imaging
Eric Ku¹, Valentina Pedoia², Matthew Tanaka³, Ursula Heilmeier¹, John Imboden⁴, Jonathan D. Graf⁵, Thomas M. Link⁶ and Xiaojuan Li⁷, ¹Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ²Department of Radiology & Biomedical Imaging, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, ³University of California Berkeley, Berkeley, CA, ⁴Rheumatology, Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁶Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, ⁷Radiology & Biomedical Imaging, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA
Background/Purpose: Standard assessment of Rheumatoid Arthritis (RA) on MRI relies on semi-quantitative joint space narrowing scores that are not sensitive to cartilage focal lesions or…
Abstract Number: 1341 • 2015 ACR/ARHP Annual Meeting
Imaging Growing Joints By Diffraction Enhanced-Computed Tomography Using a Synchrotron Light Source
Alan M. Rosenberg¹, Glendon Rhoades², Dean Chapman³, George Belev⁴, Sheldon Wiebe³, David Cooper³, Adelaine Wong³ and Brian Eames³, ¹Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Biomedical Engineering, University of Saskatchewan, Saskatoon, SK, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Canadian Light Source Inc, Ssasatoon, SK, Canada
Background/Purpose: This project developed a new method for evaluating growing joints by employing diffraction enhanced imaging (DEI) with computed tomography (CT) using a synchrotron light…
Abstract Number: 2008 • 2015 ACR/ARHP Annual Meeting
WISP1 Aggravates Osteoarthritis By Modulation of TGF-β Signaling and Positive Regulation of Canonical Wnt Signaling
Martijn H. van den Bosch¹, Arjen Blom¹, Azusa Maeda², Tina Kilts², Wim van den Berg¹, Floris Lafeber³, Peter van Lent¹, Marian Young² and Peter van der Kraan¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²NIDCR/NIH, Bethesda, MD, ³Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Many osteoarthritis (OA) patients show synovial activation, which is suggested to be involved in joint destruction. Previously, we found synovial overexpression of Wnt ligands in experimental…
Abstract Number: 2010 • 2015 ACR/ARHP Annual Meeting
Adenosine A2A Receptor, but Not A2B Receptor, Deletion Leads to Development of Osteoarthritis (OA) in Mice and Administration of a Liposomal Suspension of Adenosine Prevents/Treats Osteoarthritis in Rats
CARMEN CORCIULO¹, MATIN Lendhey², AUSTIN RAMME², Tuere Wilder³, ORAN KENNEDY² and Bruce Cronstein⁴, ¹Medicine, NYU-School of Medicine, New York, NY, ²Department of Orthopaedic Surgery, NYU-School of Medicine, New York, NY, ³Dept of Med, Div of Rheum, NYU School of Medicine, New York, NY, ⁴Medicine, Division of Rheumatology, NYU School of Medicine, NEW YORK, NY
Background/Purpose: Adenosine, acting at its receptors, regulates chondrocyte function and inflammation, two components of OA. Mice lacking adenosine A2A receptors (A2AR) have increasing difficulty walking…
Abstract Number: 170 • 2015 ACR/ARHP Annual Meeting
Relationship Between Finger Joint Cartilage Evaluated By Ultrasound and Clinical Characteristics in Rheumatoid Arthritis (RA)
Takehisa Ogura¹, Ayako Hirata¹, Hideki Ito², Sayaka Takenaka², Kennosuke Mizushina¹, Yuki Fujisawa¹, Naoko Yamashita¹, Munetugu Imamura², Norihide Hayashi² and Hideto Kameda¹, ¹Department of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan, ²Toho University Ohashi Medical Center, Tokyo, Japan
Background/Purpose: Joint destruction is the primary lesion by bone and cartilage damage in RA. By X-ray examination, cartilage destruction is evaluated as a joint space…
Abstract Number: 2722 • 2015 ACR/ARHP Annual Meeting
Cyclic Phosphatidic Acid (CPA) Suppresses Expression of Cartilage Degrading Enzymes Such As MMP-3, MMP-13 and Adamts-4 in Inflammatory Synovial Fibroblasts and Articular Chondrocytes Induced By IL-1 Beta and/or TNF ALFA
Ikuko Masuda^1,2, Kodo Okada³, Hisashi Yamanaka¹ and Shigeki Momohara¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Rheumatology, Jyujyo Takeda Rehabilitation Hospital, Kyoto, Japan, ³SANSHO, Co. Ltd., Tokyo, Japan
Background/Purpose: Cyclic phosphatidic acid (cPA) is one of bioactive lipid, has been implicated as an mediator of various biological effects including inhibitory effects of proliferation,…
Abstract Number: 312 • 2015 ACR/ARHP Annual Meeting
Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Yusuf Yazici¹, Timothy E. McAlindon², Roy Fleischmann³, Allan Gibofsky⁴, Nancy E. Lane⁵, Alan J. Kivitz⁶, Nebojsa Skrepnik⁷, Eddie Armas⁸, Christopher J. Swearingen¹, Anita DiFrancesco¹, Jeyanesh R. S. Tambiah¹, John Hood¹ and Marc C. Hochberg⁹, ¹Samumed, San Diego, CA, ²Tufts Medical Center, Boston, MA, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Weill Cornell Medical College and Hospital for Special Surgery, New York, NY, ⁵UC Davis Medical Center, Sacramento, CA, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Tucson Orthopaedic Institute, Tucson, AZ, ⁸Well Pharma Medical Research, Miami, FL, ⁹University of Maryland School of Medicine, Baltimore, MD, USA, Baltimore, MD
Background/Purpose: Knee osteoarthritis (OA) is characterized by the destruction of articular cartilage, subchrondral bone alterations and varying degrees of synovitis. Current OA treatments are limited…
Abstract Number: 313 • 2015 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study
Yusuf Yazici¹, Sharmila Majumdar², Timothy E. McAlindon³, Roy Fleischmann⁴, Allan Gibofsky⁵, Marc C. Hochberg⁶, Christopher J. Swearingen¹, Anita DiFrancesco¹, Jeyanesh R. S. Tambiah¹, John Hood¹ and Nancy E. Lane⁷, ¹Samumed, San Diego, CA, ²Radiology, UCSF School of Medicine, San Francisco, CA, ³Rheumatology, Tufts Medical Center, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Weill Cornell Medical College and Hospital for Special Surgery, New York, NY, ⁶Department of Medicine, University of Maryland, Baltimore, MD, ⁷Center for Musculoskeletal Health, Univ of California at Davis, Sacramento, CA
Background/Purpose: Knee osteoarthritis (OA) is characterized by the destruction of articular cartilage, subchrondral bone alterations and varying degrees of synovitis. Current OA treatments are limited…
Abstract Number: 315 • 2015 ACR/ARHP Annual Meeting
Structural Effects of Sprifermin in Knee Osteoarthritis: A Post-Hoc Analysis on Cartilage and Non-Cartilaginous Tissue Alterations
Frank Roemer¹, Aida Aydemir², Stefan Lohmander³, Michel Crema⁴, Monica D. Marra⁵, Norma Muurahainen², Felix Eckstein⁶ and Ali Guermazi⁷, ¹Radiology, Boston University School of Medicine, Boston, MA, ²EMD Serono, Billerica, MA, ³Lund University, Lund, Sweden, ⁴Department of Radiology, Boston University School of Medicine, Boston, MA, ⁵Department of Radiology, BUSM, Boston, MA, ⁶Paracelsus Med Univ, Chondrometrics GmbH, Salzburg, Austria, ⁷Boston University School of Medicine, Boston, MA
Background/Purpose: A randomized, double-blind, placebo-controlled phase 1b clinical trial of sprifermin (rhFGF18) in knee OA assessed central medial tibio-femoral compartment cartilage thickness on quantitative MRI…
Abstract Number: 1018 • 2015 ACR/ARHP Annual Meeting
A 32-Mer Aggrecan Fragment Generated through Adamts-4/5 and MMP-Mediated Cleavage Can Directly Excite Nociceptive Neurons
Rachel E. Miller¹, Richard J. Miller², Abdelhak Belmadani³, Suzanne Golub⁴, Amanda J. Fosang⁴ and Anne-Marie Malfait⁵, ¹Biochemistry, Rush University Medical Center, Chicago, IL, ²Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, ³Northwestern University, Chicago, IL, ⁴University of Melbourne, Melbourne, Australia, ⁵Rush University Medeical Center, Chicago, IL
Background/Purpose: Cleavage of aggrecan in the interglobular domain (E373-374A) by ADAMTS-4/5 is an early event in osteoarthritis pathogenesis. Further cleavage by MMPs (N341-342F) releases a…
Abstract Number: 1133 • 2015 ACR/ARHP Annual Meeting
Microrna-128 Interference Mitigates the Progression of Keen Osteoarthritis By Regulating Sirtuin-1
Feng-Sheng Wang¹, Yi-Chih Sun¹, Yu-Shan Chen¹ and Jih-Yang Ko², ¹Core Facility for Phenomics & Diagnostics, Department of Medical Research, Core Facility for Phenomics & Diagnostics, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan, ²Department of Orthopedic Surgery, Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, Taiwan
Background/Purpose: MicroRNAs, non-coding small RNAs, reportedly regulate development, remodeling and pathogenesis activities in various tissues through silencing mRNA targets and protein translation. This study is…
Abstract Number: 1145 • 2015 ACR/ARHP Annual Meeting
Expression of Xylosyltransferase-1 Is Modulated By Fibronectin Fragment in Human Articular Chondrocytes
Mi Hyun Lee¹, Min Ha Choi¹, Hyun Sook Hwang¹ and Hyun Ah Kim², ¹Division of rheumatology, Hallym University Sacred Heart Hospital, Kyunggi, South Korea, ²Internal Medicine, Hallym Univ Sacred Heart Hosp, Anyang, South Korea
Background/Purpose: Xylosyltransferase-1 (XT-1), encoded by xylt1 gene, is an essential anabolic enzyme to catalyze the initial and rate-determining step in glycosaminoglycan chain synthesis. The effect…

« Previous Page
1
…
7
8
9
10
11
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.